

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5996906/jorg-ellinger-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

158 papers	5,253 citations	42 h-index	66 g-index
188 ext. papers	6,075 ext. citations	4.1 avg, IF	5.33 L-index

#	Paper	IF	Citations
158	Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. <i>Cancer Research</i> , 2006 , 66, 11341-7	10.1	384
157	Circulating microRNAs (miRNA) in serum of patients with prostate cancer. <i>Urology</i> , 2011 , 77, 1265.e9-16	1.6	192
156	MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. <i>PLoS ONE</i> , 2011 , 6, e25787	3.7	187
155	Global levels of histone modifications predict prostate cancer recurrence. <i>Prostate</i> , 2010 , 70, 61-9	4.2	172
154	The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 1969-77	12.9	128
153	Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. <i>Clinical Cancer Research</i> , 2005 , 11, 4097-106	12.9	121
152	Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer. <i>Journal of Urology</i> , 2015 , 193, 331-7	2.5	118
151	CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. <i>Urology</i> , 2008 , 71, 161-7	1.6	103
150	CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. <i>Prostate</i> , 2008 , 68, 42-9	4.2	100
149	Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer?. <i>World Journal of Urology</i> , 2014 , 32, 353-8	4	95
148	Soy isoflavone genistein in prevention and treatment of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2008 , 11, 6-12	6.2	93
147	Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma. <i>Cancer Epidemiology</i> , 2012 , 36, 391-4	2.8	87
146	Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma. <i>International Journal of Cancer</i> , 2010 , 127, 2360-6	7.5	87
145	Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomy. <i>Annals of Surgical Oncology</i> , 2011 , 18, 2018-25	3.1	85
144	Primitive neuroectodermal tumor: rare, highly aggressive differential diagnosis in urologic malignancies. <i>Urology</i> , 2006 , 68, 257-62	1.6	82
143	Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma. <i>Cancer Science</i> , 2010 , 101, 2664-9	6.9	80
142	H3K4 dimethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and gastrointestinal carcinomas and correlates with expression of the methylase Ash2 and the demethylase LSD1. <i>Human Pathology</i> , 2010 , 41, 181-9	3.7	79

141	Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma. <i>International Journal of Urology</i> , 2012 , 19, 1017-25	2.3	75
140	Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012 , 30, 509-15	2.8	73
139	Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators. <i>International Journal of Cancer</i> , 2008 , 122, 138-43	7.5	72
138	CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer. <i>Journal of Urology</i> , 2009 , 182, 324-9	2.5	69
137	Identification of novel long non-coding RNAs in clear cell renal cell carcinoma. <i>Clinical Epigenetics</i> , 2015 , 7, 10	7.7	67
136	Circulating mitochondrial DNA in the serum of patients with testicular germ cell cancer as a novel noninvasive diagnostic biomarker. <i>BJU International</i> , 2009 , 104, 48-52	5.6	65
135	Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer. <i>Journal of Urology</i> , 2009 , 181, 363-71	2.5	63
134	Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomy. <i>BJU International</i> , 2008 , 102, 628-32	5.6	63
133	Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. <i>European Urology</i> , 2007 , 51, 665-74; discussion 674	10.2	62
132	PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. <i>Oncotarget</i> , 2016 , 7, 79943-79955	3.3	62
131	Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study. <i>Clinical Chemistry</i> , 2017 , 63, 1288-1296	5.5	60
130	Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy. <i>European Urology</i> , 2011 , 59, 712-8	10.2	60
129	Analysis of sex differences in cancer-specific survival and perioperative mortality following radical cystectomy: results of a large German multicenter study of nearly 2500 patients with urothelial carcinoma of the bladder. <i>Gender Medicine</i> , 2012 , 9, 481-9		58
128	Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. <i>Journal of Urology</i> , 2008 , 179, 346-52	2.5	58
127	Global histone H4K20 trimethylation predicts cancer-specific survival in patients with muscle-invasive bladder cancer. <i>BJU International</i> , 2011 , 108, E290-6	5.6	54
126	Global histone H3 lysine 27 (H3K27) methylation levels and their prognostic relevance in renal cell carcinoma. <i>BJU International</i> , 2012 , 109, 459-65	5.6	53
125	Apoptotic DNA fragments in serum of patients with muscle invasive bladder cancer: a prognostic entity. <i>Cancer Letters</i> , 2008 , 264, 274-80	9.9	51
124	KDM5C is overexpressed in prostate cancer and is a prognostic marker for prostate-specific antigen-relapse following radical prostatectomy. <i>American Journal of Pathology</i> , 2014 , 184, 2430-7	5.8	48

123	Identification of aberrant tRNA-halves expression patterns in clear cell renal cell carcinoma. <i>Scientific Reports</i> , 2016 , 6, 37158	4.9	47
122	Serum miR-122-5p and miR-206 expression: non-invasive prognostic biomarkers for renal cell carcinoma. <i>Clinical Epigenetics</i> , 2018 , 10, 11	7.7	46
121	Epigenetic biomarkers in the blood of patients with urological malignancies. <i>Expert Review of Molecular Diagnostics</i> , 2015 , 15, 505-16	3.8	45
120	Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 1141-7	2.8	45
119	Global histone H3K27 methylation levels are different in localized and metastatic prostate cancer. <i>Cancer Investigation</i> , 2012 , 30, 92-7	2.1	44
118	Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma. <i>Molecular Cancer</i> , 2016 , 15, 10	42.1	43
117	Rationale for treatment of metastatic squamous cell carcinoma of the lung using fibroblast growth factor receptor inhibitors. <i>Chest</i> , 2012 , 142, 1020-1026	5.3	43
116	The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011 , 29, 124-9	2.8	42
115	Alterations of global histone H4K20 methylation during prostate carcinogenesis. <i>BMC Urology</i> , 2012 , 12, 5	2.2	41
114	Stem cell marker expression in small cell lung carcinoma and developing lung tissue. <i>Human Pathology</i> , 2008 , 39, 1597-605	3.7	41
113	Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role. <i>Journal of Urology</i> , 2018 , 199, 370-377	2.5	40
112	Tomatoes, tomato products and lycopene in the prevention and treatment of prostate cancer: do we have the evidence from intervention studies?. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2006 , 9, 722-7	3.8	40
111	Serum DNA hypermethylation in patients with kidney cancer: results of a prospective study. <i>Anticancer Research</i> , 2013 , 33, 4651-6	2.3	39
110	Promoter methylation of the immune checkpoint receptor () is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. <i>Oncolmmunology</i> , 2016 , 5, e1221555	7.2	37
109	Kinetics of L-theanine uptake and metabolism in healthy participants are comparable after ingestion of L-theanine via capsules and green tea. <i>Journal of Nutrition</i> , 2012 , 142, 2091-6	4.1	36
108	Serum microRNAs as biomarkers in patients undergoing prostate biopsy: results from a prospective multi-center study. <i>Anticancer Research</i> , 2014 , 34, 665-9	2.3	36
107	The peripheral zone of the prostate is more prone to tumor development than the transitional zone: is the ETS family the key?. <i>Molecular Medicine Reports</i> , 2012 , 5, 313-6	2.9	34
106	The N -methyladenosine (m A) erasers alkylation repair homologue 5 (ALKBH5) and fat mass and obesity-associated protein (FTO) are prognostic biomarkers in patients with clear cell renal carcinoma. <i>BJU International</i> , 2020 , 125, 617-624	5.6	31

105	Tyrosine kinase expression profile in clear cell renal cell carcinoma. <i>World Journal of Urology</i> , 2012 , 30, 559-65	4	31
104	Analysis of tissue and serum microRNA expression in patients with upper urinary tract urothelial cancer. <i>PLoS ONE</i> , 2015 , 10, e0117284	3.7	31
103	The long non-coding RNA lnc-ZNF180-2 is a prognostic biomarker in patients with clear cell renal cell carcinoma. <i>American Journal of Cancer Research</i> , 2015 , 5, 2799-807	4.4	31
102	CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients. <i>Oncotarget</i> , 2016 , 7, 53309-53320	3.3	31
101	PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies. <i>Journal of Molecular Diagnostics</i> , 2017 , 19, 107-114	5.1	30
100	Testicular seminoma clinical stage 1: treatment outcome on a routine care level. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016 , 142, 1599-607	4.9	30
99	5qRNA Halves are Dysregulated in Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2018 , 199, 378-383	3.5	30
98	Thulium laser (Revolix) vapoenucleation of the prostate is a safe procedure in patients with an increased risk of hemorrhage. <i>Urologia Internationalis</i> , 2012 , 88, 390-4	1.9	29
97	CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients. <i>Epigenetics</i> , 2016 , 11, 871-880	5.7	29
96	() DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma 2020 , 8,		28
95	Nucleic acid-based tissue biomarkers of urologic malignancies. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2014 , 51, 173-99	9.4	28
94	Identification of novel differentially expressed lncRNA and mRNA transcripts in clear cell renal cell carcinoma by expression profiling. <i>Genomics Data</i> , 2015 , 5, 173-5		27
93	Systematic Analysis of the Expression of the Mitochondrial ATP Synthase (Complex V) Subunits in Clear Cell Renal Cell Carcinoma. <i>Translational Oncology</i> , 2017 , 10, 661-668	4.9	27
92	Evidence from the PROspective MulticEnTer Radical Cystectomy Series 2011 (PROMETRICS 2011)Q study: how are preoperative patient characteristics associated with urinary diversion type after radical cystectomy for bladder cancer?. <i>Annals of Surgical Oncology</i> , 2015 , 22, 1032-42	3.1	26
91	Enhanced expression of peroxisome proliferate-activated receptor gamma (PPAR- γ) in advanced prostate cancer. <i>Anticancer Research</i> , 2012 , 32, 3479-83	2.3	26
90	Alterations of global histone H3K9 and H3K27 methylation levels in bladder cancer. <i>Urologia Internationalis</i> , 2014 , 93, 113-8	1.9	24
89	Influence of Body Mass Index on Clinical Outcome Parameters, Complication Rate and Survival after Radical Cystectomy: Evidence from a Prospective European Multicentre Study. <i>Urologia Internationalis</i> , 2018 , 101, 16-24	1.9	23
88	Serum DNA hypermethylation in patients with bladder cancer: results of a prospective multicenter study. <i>Anticancer Research</i> , 2013 , 33, 779-84	2.3	22

87	DNA hypermethylation in papillary renal cell carcinoma. <i>BJU International</i> , 2011 , 107, 664-9	5.6	21
86	Decreased levels of histone H3K9me1 indicate poor prognosis in patients with renal cell carcinoma. <i>Anticancer Research</i> , 2012 , 32, 879-86	2.3	21
85	Comprehensive analysis of the transcriptional profile of the Mediator complex across human cancer types. <i>Oncotarget</i> , 2016 , 7, 23043-55	3.3	20
84	tRNA-halves are prognostic biomarkers for patients with prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 503.e1-503.e7	2.8	20
83	Systematic expression analysis of the mitochondrial complex III subunits identifies UQCRC1 as biomarker in clear cell renal cell carcinoma. <i>Oncotarget</i> , 2016 , 7, 86490-86499	3.3	18
82	Effect of Hospital and Surgeon Case Volume on Perioperative Quality of Care and Short-term Outcomes After Radical Cystectomy for Muscle-invasive Bladder Cancer: Results From a European Tertiary Care Center Cohort. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e809-e817	3.3	17
81	YRNA Expression Profiles are Altered in Clear Cell Renal Cell Carcinoma. <i>European Urology Focus</i> , 2018 , 4, 260-266	5.1	17
80	ISL1 is a major susceptibility gene for classic bladder exstrophy and a regulator of urinary tract development. <i>Scientific Reports</i> , 2017 , 7, 42170	4.9	16
79	Optimizing outcome reporting after radical cystectomy for organ-confined urothelial carcinoma of the bladder using oncological trifecta and pentapecta. <i>World Journal of Urology</i> , 2015 , 33, 1945-50	4	16
78	Prognostic significance of venous tumour thrombus consistency in patients with renal cell carcinoma (RCC). <i>BJU International</i> , 2014 , 113, 209-17	5.6	16
77	YRNA expression predicts survival in bladder cancer patients. <i>BMC Cancer</i> , 2017 , 17, 749	4.8	15
76	Epigenetic regulation of microRNA expression in renal cell carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2013 , 436, 79-84	3.4	15
75	Bolus consumption of a specifically designed fruit juice rich in anthocyanins and ascorbic acid did not influence markers of antioxidative defense in healthy humans. <i>Journal of Agricultural and Food Chemistry</i> , 2012 , 60, 11292-300	5.7	15
74	Comparison of myocardial remodeling between cryoinfarction and reperfused infarction in mice. <i>Journal of Biomedicine and Biotechnology</i> , 2011 , 2011, 961298		15
73	Evaluation of Global Histone Acetylation Levels in Bladder Cancer Patients. <i>Anticancer Research</i> , 2016 , 36, 3961-4	2.3	15
72	The emerging role of non-coding circulating RNA as a biomarker in renal cell carcinoma. <i>Expert Review of Molecular Diagnostics</i> , 2016 , 16, 1059-1065	3.8	14
71	Apelin and apelin receptor expression in renal cell carcinoma. <i>British Journal of Cancer</i> , 2019 , 120, 633-639	3.7	14
70	Mitochondrial PIWI-interacting RNAs are novel biomarkers for clear cell renal cell carcinoma. <i>World Journal of Urology</i> , 2019 , 37, 1639-1647	4	13

69	YRNA expression in prostate cancer patients: diagnostic and prognostic implications. <i>World Journal of Urology</i> , 2018 , 36, 1073-1078	4	12
68	Pathological upstaging detected in radical cystectomy procedures is associated with a significantly worse tumour-specific survival rate for patients with clinical T1 urothelial carcinoma of the urinary bladder. <i>Scandinavian Journal of Urology and Nephrology</i> , 2011 , 45, 251-7		12
67	Prediction of outcome in patients with urothelial carcinoma of the bladder following radical cystectomy using artificial neural networks. <i>European Journal of Surgical Oncology</i> , 2013 , 39, 372-9	3.6	11
66	Glutathione-S-transferase pi 1(GSTP1) gene silencing in prostate cancer cells is reversed by the histone deacetylase inhibitor depsipeptide. <i>Biochemical and Biophysical Research Communications</i> , 2011 , 412, 606-11	3.4	11
65	Multicenter evaluation of the prognostic value of pT0 stage after radical cystectomy due to urothelial carcinoma of the bladder. <i>BJU International</i> , 2011 , 108, E278-83	5.6	10
64	Saturation biopsy improves preoperative Gleason scoring of prostate cancer. <i>Pathology Research and Practice</i> , 2009 , 205, 259-64	3.4	10
63	DNA Methylation and Bladder Cancer: Where Genotype does not Predict Phenotype. <i>Current Genomics</i> , 2020 , 21, 34-36	2.6	10
62	Cultivation of Clear Cell Renal Cell Carcinoma Patient-Derived Organoids in an Air-Liquid Interface System as a Tool for Studying Individualized Therapy. <i>Frontiers in Oncology</i> , 2020 , 10, 1775	5.3	10
61	Seminoma Clinical Stage 1 - Patterns of Care in Germany. <i>Urologia Internationalis</i> , 2016 , 96, 390-8	1.9	10
60	Expression of programmed cell death protein 4 (PDCD4) and miR-21 in urothelial carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2012 , 417, 29-34	3.4	9
59	External validation of disease-free survival at 2 or 3 years as a surrogate and new primary endpoint for patients undergoing radical cystectomy for urothelial carcinoma of the bladder. <i>European Journal of Surgical Oncology</i> , 2012 , 38, 637-42	3.6	9
58	Prostaglandin receptors EP1-4 as a potential marker for clinical outcome in urothelial bladder cancer. <i>American Journal of Cancer Research</i> , 2014 , 4, 952-62	4.4	9
57	Cell-Free DNA Methylation in Blood as a Molecular Staging Parameter for Risk Stratification in Renal Cell Carcinoma Patients: A Prospective Observational Cohort Study. <i>Clinical Chemistry</i> , 2019 , 65, 559-568	5.5	9
56	Systematic Expression Analysis of Mitochondrial Complex I Identifies NDUFS1 as a Biomarker in Clear-Cell Renal-Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e551-e562	3.3	8
55	promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy. <i>Clinical Epigenetics</i> , 2016 , 8, 104	7.7	8
54	Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression. <i>Frontiers in Medicine</i> , 2017 , 4, 30	4.9	8
53	Differential expression of Mediator complex subunit MED15 in testicular germ cell tumors. <i>Diagnostic Pathology</i> , 2015 , 10, 165	3	8
52	NDUFA4 expression in clear cell renal cell carcinoma is predictive for cancer-specific survival. <i>American Journal of Cancer Research</i> , 2015 , 5, 2816-22	4.4	8

51	and DNA Methylation Biomarker Test (EI-BLA) for Urine-Based Non-Invasive Detection of Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	8
50	The lncRNA Fer1L4 is an adverse prognostic parameter in clear-cell renal-cell carcinoma. <i>Clinical and Translational Oncology</i> , 2020 , 22, 1524-1531	3.6	7
49	Classic bladder exstrophy and adenocarcinoma of the bladder: Methylome analysis provide no evidence for underlying disease-mechanisms of this association. <i>Cancer Genetics</i> , 2019 , 235-236, 18-20	2.3	7
48	External validation of a risk model to predict recurrence-free survival after radical cystectomy in patients with pathological tumor stage T3N0 urothelial carcinoma of the bladder. <i>Journal of Urology</i> , 2012 , 187, 1210-4	2.5	7
47	Histone methylation defines an epigenetic entity in penile squamous cell carcinoma. <i>Journal of Urology</i> , 2013 , 189, 1117-22	2.5	7
46	MicroRNAs: a novel non-invasive biomarker for patients with urological malignancies. <i>Current Pharmaceutical Biotechnology</i> , 2014 , 15, 486-91	2.6	7
45	Identification of miR-21-5p and miR-210-3p serum levels as biomarkers for patients with papillary renal cell carcinoma: a multicenter analysis. <i>Translational Andrology and Urology</i> , 2020 , 9, 1314-1322	2.3	7
44	CircEHD2, CircNETO2 and CircEGLN3 as Diagnostic and Prognostic Biomarkers for Patients with Renal Cell Carcinoma. <i>Cancers</i> , 2021 , 13,	6.6	7
43	Karyopherin Alpha 2 Is an Adverse Prognostic Factor in Clear-Cell and Papillary Renal-Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e167-e175	3.3	7
42	Spindle cell rhabdomyosarcoma of the prostate. <i>International Journal of Urology</i> , 2013 , 20, 935-7	2.3	6
41	Loss of cadherin related family member 5 (CDHR5) expression in clear cell renal cell carcinoma is a prognostic marker of disease progression. <i>Oncotarget</i> , 2017 , 8, 75076-75086	3.3	6
40	The Mediator complex subunit MED15, a promoter of tumour progression and metastatic spread in renal cell carcinoma. <i>Cancer Biomarkers</i> , 2018 , 21, 839-847	3.8	5
39	Identification of immunity-related genes in prostate cancer and potential role of the ETS family of transcription factors in their regulation. <i>International Journal of Molecular Medicine</i> , 2011 , 28, 799-807	4.4	5
38	Low Plasma Appearance of (+)-Catechin and (-)-Catechin Compared with Epicatechin after Consumption of Beverages Prepared from Nonalkalized or Alkalized Cocoa-A Randomized, Double-Blind Trial. <i>Nutrients</i> , 2020 , 12,	6.7	5
37	Clinical Studies Applying Cytokine-Induced Killer Cells for the Treatment of Renal Cell Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	5
36	Targeting glycolysis with 2-deoxy-D-glucose sensitizes primary cell cultures of renal cell carcinoma to tyrosine kinase inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 2255-2265	4.9	4
35	Systematic expression analysis of the mitochondrial respiratory chain protein subunits identifies COX5B as a prognostic marker in clear cell renal cell carcinoma. <i>International Journal of Urology</i> , 2019 , 26, 910-916	2.3	4
34	Identification of prostaglandin receptors in human ureters. <i>BMC Urology</i> , 2012 , 12, 35	2.2	4

33	Pathological outcomes of men eligible for active surveillance after undergoing radical prostatectomy: are results predictable?. <i>Clinical Genitourinary Cancer</i> , 2012 , 10, 32-6	3.3	4
32	Genes differentially expressed in the peripheral zone compared to the transitional zone of the normal human prostate and their potential regulation by ETS factors. <i>Molecular Medicine Reports</i> , 2012 , 5, 32-6	2.9	4
31	The knockdown of the mediator complex subunit MED30 suppresses the proliferation and migration of renal cell carcinoma cells. <i>Annals of Diagnostic Pathology</i> , 2018 , 34, 18-26	2.2	3
30	Cytoplasmatic and Nuclear YAP1 and pYAP1 Staining in Urothelial Bladder Cancer. <i>Urologia Internationalis</i> , 2016 , 96, 39-45	1.9	3
29	The knockdown of the Mediator complex subunit MED15 restrains urothelial bladder cancer cellsQ malignancy. <i>Oncology Letters</i> , 2018 , 16, 3013-3021	2.6	3
28	Clinical and pathological nodal staging score for urothelial carcinoma of the bladder: an external validation. <i>World Journal of Urology</i> , 2014 , 32, 365-71	4	3
27	The Contrasting Role of the Mediator Subunit MED30 in the Progression of Bladder Cancer. <i>Anticancer Research</i> , 2017 , 37, 6685-6695	2.3	3
26	Lutetium-177-prostate-specific membrane antigen ligand following radium-223 treatment in men with bone-metastatic castration-resistant prostate cancer: real-world clinical experience. <i>Journal of Nuclear Medicine</i> , 2021 ,	8.9	3
25	Prognostic role of TSPAN1, KIAA1324 and ESRP1 in prostate cancer. <i>Apmis</i> , 2021 , 129, 204-212	3.4	3
24	A Multi-institutional Pooled Analysis Demonstrates That Circulating miR-371a-3p Alone is Sufficient for Testicular Malignant Germ Cell Tumor Diagnosis. <i>Clinical Genitourinary Cancer</i> , 2021 ,	3.3	3
23	Downstream neighbor of SON (DONSON) is associated with unfavorable survival across diverse cancers with oncogenic properties in clear cell renal cell carcinoma. <i>Translational Oncology</i> , 2020 , 13, 100844	4.9	2
22	The contrasting roles of Dysferlin during tumor progression in renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 687.e1-687.e11	2.8	2
21	Fungaemia caused by obstructive renal candida bezoars leads to bilateral chorioretinitis: a case report. <i>BMC Urology</i> , 2018 , 18, 21	2.2	2
20	Diagnostic meaning of urodynamic studies in pouch incontinence: results of a small series. <i>Urologia Internationalis</i> , 2014 , 92, 237-41	1.9	2
19	Systemic Effects Reflected in Specific Biomarker Patterns Are Instrumental for the Paradigm Change in Prostate Cancer Management: A Strategic Paper.. <i>Cancers</i> , 2022 , 14,	6.6	2
18	Mitophagy-associated genes PINK1 and PARK2 are independent prognostic markers of survival in papillary renal cell carcinoma and associated with aggressive tumor behavior. <i>Scientific Reports</i> , 2020 , 10, 18857	4.9	2
17	N -Methyladenosine (m A) readers are dysregulated in renal cell carcinoma. <i>Molecular Carcinogenesis</i> , 2021 , 60, 354-362	5	2
16	promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma 2021 , 9,		2

15	Evaluation of Serum Biomarkers (FGF-2, HGF, MIF and PTN) in Patients With Testicular Germ Cell Cancer. <i>In Vivo</i> , 2019 , 33, 1935-1940	2.3	1
14	High grade adenocarcinoma in the ectopic prostate accompanied by a low grade adenocarcinoma in the orthotopic prostate: an unusual diagnostic pitfall. <i>Pathology</i> , 2017 , 49, 665-668	1.6	1
13	Disease characteristics and outcome of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received a beta emitter (177Lu-PSMA) after an alpha emitter (radium-223).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e17592-e17592	2.2	1
12	C-reactive protein flare-response predicts long-term efficacy to first-line anti-PD-1-based combination therapy in metastatic renal cell carcinoma.. <i>Clinical and Translational Immunology</i> , 2021 , 10, e1358	6.8	1
11	Comprehensive Analysis of the ATP-binding Cassette Subfamily B Across Renal Cancers Identifies ABCB8 Overexpression in Phenotypically Aggressive Clear Cell Renal Cell Carcinoma. <i>European Urology Focus</i> , 2021 , 7, 1121-1129	5.1	1
10	Downstream Neighbor of SON (DONSON) Expression Is Enhanced in Phenotypically Aggressive Prostate Cancers. <i>Cancers</i> , 2020 , 12,	6.6	1
9	DNA Promoter Methylation and ERG Regulate the Expression of CD24 in Prostate Cancer. <i>American Journal of Pathology</i> , 2021 , 191, 618-630	5.8	1
8	Systematic expression analysis of mA RNA methyltransferases in clear cell renal cell carcinoma.. <i>BJUI Compass</i> , 2021 , 2, 402-411	0.9	1
7	Pelvic Exenteration in Advanced Gynecologic Malignancies - Who Will Benefit?. <i>Anticancer Research</i> , 2021 , 41, 3037-3043	2.3	1
6	MicroRNA-profiling of miR-371~373- and miR-302/367-clusters in serum and cerebrospinal fluid identify patients with intracranial germ cell tumors.. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022 , 1	4.9	1
5	Otoferlin is a prognostic biomarker in patients with clear cell renal cell carcinoma: A systematic expression analysis. <i>International Journal of Urology</i> , 2021 , 28, 424-431	2.3	0
4	Comparison of First-Line Anti-PD-1-Based Combination Therapies in Metastatic Renal-Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort.. <i>Urologia Internationalis</i> , 2022 , 1-8	1.9	0
3	C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma.. <i>European Journal of Cancer</i> , 2022 , 167, 13-22	7.5	0
2	Primary Urethral Plasmacytoma Treated with High-Dose-Rate Brachytherapy: A Case Report. <i>Urologia Internationalis</i> , 2016 , 97, 369-372	1.9	
1	First report of an unexpected blind-ending duplication of the ureter as a rare pitfall in kidney transplantation. <i>Transplant International</i> , 2008 , 21, 696-7	3	